País: Estados Unidos
Idioma: inglés
Fuente: NLM (National Library of Medicine)
CALCITRIOL (UNII: FXC9231JVH) (CALCITRIOL - UNII:FXC9231JVH)
Golden State Medical Supply, Inc.
ORAL
PRESCRIPTION DRUG
Calcitriol capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Calcitriol capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol capsules administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Calcitriol capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. Calcitriol should not be given to patients with hypercalcemia or evidence of vitamin D toxicity. Use of calcitriol in patients with known hypersensitivity to calcitriol (or drugs of the same class) or any of the inactive ingredients is contraindicated.
Capsules: 0.25 mcg calcitriol in soft gelatin, light orange, oval capsules, imprinted with CAL1 in black ink; bottles of 30 (NDC 51407-169-30), and bottles of 100 (NDC 51407-169-01). Capsules: 0.5 mcg calcitriol in soft gelatin, dark orange-red, oval capsules, imprinted with CAL2 in black ink; bottles of 100 (NDC 51407-170-01). Calcitriol Capsules should be protected from light. Store at 20° to 25°C (68°-77°F) [see USP Controlled Room Temperature]. Manufactured for: Bionpharma Inc. Princeton, NJ 08540, USA Rev. 02/23 Marketed by: GSMS, Inc. Camarillo, CA 93012 USA
Abbreviated New Drug Application
CALCITRIOL- CALCITRIOL CAPSULE, LIQUID FILLED GOLDEN STATE MEDICAL SUPPLY, INC. ---------- CALCITRIOL CAPSULE, LIQUID FILLED RX ONLY DESCRIPTION Calcitriol is a synthetic vitamin D analog which is active in the regulation of the absorption of calcium from the gastrointestinal tract and its utilization in the body. Calcitriol Capsules contain 0.25 mcg or 0.5 mcg calcitriol, fractionated triglyceride of coconut oil, butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) as antioxidants. Gelatin capsule shells contain glycerin, water, sorbitol, sorbitan, mannitol, water, FD&C Yellow No. 6, FD&C Red #40, titanium dioxide and iron oxide black. Calcitriol is a white, crystalline compound which occurs naturally in humans. It has a calculated molecular weight of 416.65 and is soluble in organic solvents but relatively insoluble in water. Chemically, calcitriol is 9,10- seco(5Z,7E)-5,7,10(19)-cholestatriene- 1α, 3β, 25-triol and has the following structural formula: The other names frequently used for calcitriol are 1α,25-dihydroxycholecalciferol, 1,25- dihydroxyvitamin D , 1,25-DHCC, 1,25(OH) D and 1,25-diOHC. CLINICAL PHARMACOLOGY Man's natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin D (cholecalciferol). Vitamin D must be metabolically activated in the liver and the kidney before it is fully active as a regulator of calcium and phosphorus metabolism at target tissues. The initial transformation of vitamin D is catalyzed by a vitamin D -25-hydroxylase enzyme (25- OHase) present in the liver, and the product of this reaction is 25 hydroxyvitamin D [25-(OH)D ]. Hydroxylation of 25-(OH)D occurs in the mitochondria of kidney tissue, activated by the renal 25-hydroxyvitamin D -1 alpha-hydroxylase (alpha-OHase), to produce 1,25-(OH) D (calcitriol), the active form of vitamin D . Endogenous synthesis and catabolism of calcitriol, as well as physiological control mechanisms affecting these 3 2 3 3 3 3 3 3 3 3 3 2 Leer el documento completo